Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroendocrine Tumors 1Neoplasms 1Malignant Solid Tumour 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Glioblastoma 1Castrate-resistant Prostate Cancer 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Radiosurgery 113Temozolomide 104Bevacizumab 70Radiotherapy 66Magnetic Resonance Spectroscopy 66Carboplatin 29pembrolizumab 27Irinotecan 26Surgical Procedures, Operative 25Nivolumab 23Radiation 22Etoposide 22Magnetic Resonance Imaging 21Ipilimumab 21Erlotinib Hydrochloride 21Cyclophosphamide 21Surveys and Questionnaires 19Aminolevulinic Acid 18Specimen Handling 16Pemetrexed 16Mental Status and Dementia Tests 16Cisplatin 16Carmustine 15Topotecan 14Trastuzumab 13Saline Solution 12Neuropsychological Tests 12Gefitinib 11Filgrastim 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Brain Neoplasms × dactolisib × Clear all
NCT01508104 2017-08-23

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

University of Cincinnati

Phase 1 Terminated
19 enrolled
CNSEndocrineNET

Brain Neoplasms, Glioblastoma, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡